Subsidiary of China Meheco Group (600056.SH) obtains registration approval for Rosuvastatin Ezetimibe Tablets (I) drug.
China Medicine (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (Tianfang Pharmaceutical) recently received the approval and issuance of the Drug Registration Certificate for Rosuvastatin Ezetimibe Tablets (I) from the National Medical Products Administration. Rosuvastatin Ezetimibe Tablets are mainly used to treat hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). Ezetimibe combined with rosuvastatin calcium can synergistically increase efficacy in lowering lipid levels and reduce cardiovascular events.
China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical"), has recently received the Drug Registration Certificate for Rosuvastatin Ezetimibe Tablets (I) issued by the National Medical Products Administration. Rosuvastatin Ezetimibe Tablets are mainly used for the treatment of high cholesterol and homozygous familial hypercholesterolemia (HoFH). The combination of Ezetimibe and Rosuvastatin can synergistically enhance the efficacy of lowering blood lipids and reduce cardiovascular events.
Related Articles
New China Life Insurance (01336): Yang Yucheng is elected as Chairman.
HUISHANG BANK (03698): Wei Lixiang's qualifications as a non-executive director have been approved for appointment.
"Visual Area Technology's science and technology innovation board IPO passed last year, with the shipment volume of silicon-based OLED products ranking second in the world."
New China Life Insurance (01336): Yang Yucheng is elected as Chairman.
HUISHANG BANK (03698): Wei Lixiang's qualifications as a non-executive director have been approved for appointment.
"Visual Area Technology's science and technology innovation board IPO passed last year, with the shipment volume of silicon-based OLED products ranking second in the world."
RECOMMEND
